Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
Altis® 522 Trial - Treatment of Female Stress Urinary Incontinence
The aim of this postmarket study is to compare the safety and effectiveness of the Altis Single Incision Sling (SIS) to an FDA cleared transobturator and/or retropubic sling through 36 months.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Transobturator or Retropubic Sling
- device: Altis Single Incision Sling
Eligibility
Inclusion Criteria:
- The subject is female and at least 18 years of age.
- The subject is able and willing to complete all procedures and follow-up visits
indicated in this protocol.
- The subject has confirmed stress urinary incontinence (SUI) through cough stress test
or urodynamics.
- The subject has failed two non-invasive incontinence therapies (such as Kegel
exercise, behavior modification, pad use, biofeedback, etc.) for > 6 months.
Exclusion Criteria:
- The subject has an active urogenital infection or active skin infection in region of
surgery.
- The subject has confirmed Pelvic Organ Prolapse (POP) of Stage 2 or higher as
determined by POP-Q prolapse grading.
- The subject is having a concomitant pelvic floor procedure.
- The subject has incontinence due to neurogenic causes (e.g. multiple sclerosis, spinal
cord/brain injury, cerebrovascular accident, detrusor-external sphincter dyssynergia,
Parkinson's disease, or similar conditions).
- The subject had a prior surgical stress urinary incontinence (SUI) treatment.
- The subject has undergone radiation or brachy therapy to treat pelvic cancer.
- The subject has urge predominant incontinence by MESA assessment.
- The subject has an atonic bladder or post void residual (PVR) above 100 cc on ≥ 2
occasions.
- The subject is pregnant and/or is planning to get pregnant in the future.
- The subject has a contraindication to the surgical procedure or the product
Instructions for Use (IFU).
- The subject is enrolled in a concurrent clinical trial of any treatment (drug or
device) that could affect continence function, without the sponsors approval.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
Female
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kathryn Batham
650-724-7846
I'm interested
Psoriasis Clinical Trials
Altis® 522 Trial - Treatment of Female Stress Urinary Incontinence
The aim of this postmarket study is to compare the safety and effectiveness of the Altis Single Incision Sling (SIS) to an FDA cleared transobturator and/or retropubic sling through 36 months.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Transobturator or Retropubic Sling
- device: Altis Single Incision Sling
Eligibility
Inclusion Criteria:
- The subject is female and at least 18 years of age.
- The subject is able and willing to complete all procedures and follow-up visits
indicated in this protocol.
- The subject has confirmed stress urinary incontinence (SUI) through cough stress test
or urodynamics.
- The subject has failed two non-invasive incontinence therapies (such as Kegel
exercise, behavior modification, pad use, biofeedback, etc.) for > 6 months.
Exclusion Criteria:
- The subject has an active urogenital infection or active skin infection in region of
surgery.
- The subject has confirmed Pelvic Organ Prolapse (POP) of Stage 2 or higher as
determined by POP-Q prolapse grading.
- The subject is having a concomitant pelvic floor procedure.
- The subject has incontinence due to neurogenic causes (e.g. multiple sclerosis, spinal
cord/brain injury, cerebrovascular accident, detrusor-external sphincter dyssynergia,
Parkinson's disease, or similar conditions).
- The subject had a prior surgical stress urinary incontinence (SUI) treatment.
- The subject has undergone radiation or brachy therapy to treat pelvic cancer.
- The subject has urge predominant incontinence by MESA assessment.
- The subject has an atonic bladder or post void residual (PVR) above 100 cc on ≥ 2
occasions.
- The subject is pregnant and/or is planning to get pregnant in the future.
- The subject has a contraindication to the surgical procedure or the product
Instructions for Use (IFU).
- The subject is enrolled in a concurrent clinical trial of any treatment (drug or
device) that could affect continence function, without the sponsors approval.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
Female
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kathryn Batham
650-724-7846
I'm interested
Dermatology Clinical Trials
Altis® 522 Trial - Treatment of Female Stress Urinary Incontinence
The aim of this postmarket study is to compare the safety and effectiveness of the Altis Single Incision Sling (SIS) to an FDA cleared transobturator and/or retropubic sling through 36 months.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Transobturator or Retropubic Sling
- device: Altis Single Incision Sling
Eligibility
Inclusion Criteria:
- The subject is female and at least 18 years of age.
- The subject is able and willing to complete all procedures and follow-up visits
indicated in this protocol.
- The subject has confirmed stress urinary incontinence (SUI) through cough stress test
or urodynamics.
- The subject has failed two non-invasive incontinence therapies (such as Kegel
exercise, behavior modification, pad use, biofeedback, etc.) for > 6 months.
Exclusion Criteria:
- The subject has an active urogenital infection or active skin infection in region of
surgery.
- The subject has confirmed Pelvic Organ Prolapse (POP) of Stage 2 or higher as
determined by POP-Q prolapse grading.
- The subject is having a concomitant pelvic floor procedure.
- The subject has incontinence due to neurogenic causes (e.g. multiple sclerosis, spinal
cord/brain injury, cerebrovascular accident, detrusor-external sphincter dyssynergia,
Parkinson's disease, or similar conditions).
- The subject had a prior surgical stress urinary incontinence (SUI) treatment.
- The subject has undergone radiation or brachy therapy to treat pelvic cancer.
- The subject has urge predominant incontinence by MESA assessment.
- The subject has an atonic bladder or post void residual (PVR) above 100 cc on ≥ 2
occasions.
- The subject is pregnant and/or is planning to get pregnant in the future.
- The subject has a contraindication to the surgical procedure or the product
Instructions for Use (IFU).
- The subject is enrolled in a concurrent clinical trial of any treatment (drug or
device) that could affect continence function, without the sponsors approval.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
Female
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kathryn Batham
650-724-7846
I'm interested
Pediatric Dermatology Clinical Trials
Altis® 522 Trial - Treatment of Female Stress Urinary Incontinence
The aim of this postmarket study is to compare the safety and effectiveness of the Altis Single Incision Sling (SIS) to an FDA cleared transobturator and/or retropubic sling through 36 months.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Transobturator or Retropubic Sling
- device: Altis Single Incision Sling
Eligibility
Inclusion Criteria:
- The subject is female and at least 18 years of age.
- The subject is able and willing to complete all procedures and follow-up visits
indicated in this protocol.
- The subject has confirmed stress urinary incontinence (SUI) through cough stress test
or urodynamics.
- The subject has failed two non-invasive incontinence therapies (such as Kegel
exercise, behavior modification, pad use, biofeedback, etc.) for > 6 months.
Exclusion Criteria:
- The subject has an active urogenital infection or active skin infection in region of
surgery.
- The subject has confirmed Pelvic Organ Prolapse (POP) of Stage 2 or higher as
determined by POP-Q prolapse grading.
- The subject is having a concomitant pelvic floor procedure.
- The subject has incontinence due to neurogenic causes (e.g. multiple sclerosis, spinal
cord/brain injury, cerebrovascular accident, detrusor-external sphincter dyssynergia,
Parkinson's disease, or similar conditions).
- The subject had a prior surgical stress urinary incontinence (SUI) treatment.
- The subject has undergone radiation or brachy therapy to treat pelvic cancer.
- The subject has urge predominant incontinence by MESA assessment.
- The subject has an atonic bladder or post void residual (PVR) above 100 cc on ≥ 2
occasions.
- The subject is pregnant and/or is planning to get pregnant in the future.
- The subject has a contraindication to the surgical procedure or the product
Instructions for Use (IFU).
- The subject is enrolled in a concurrent clinical trial of any treatment (drug or
device) that could affect continence function, without the sponsors approval.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
Female
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kathryn Batham
650-724-7846
I'm interested
Altis® 522 Trial - Treatment of Female Stress Urinary Incontinence
The aim of this postmarket study is to compare the safety and effectiveness of the Altis Single Incision Sling (SIS) to an FDA cleared transobturator and/or retropubic sling through 36 months.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Transobturator or Retropubic Sling
- device: Altis Single Incision Sling
Eligibility
Inclusion Criteria:
- The subject is female and at least 18 years of age.
- The subject is able and willing to complete all procedures and follow-up visits
indicated in this protocol.
- The subject has confirmed stress urinary incontinence (SUI) through cough stress test
or urodynamics.
- The subject has failed two non-invasive incontinence therapies (such as Kegel
exercise, behavior modification, pad use, biofeedback, etc.) for > 6 months.
Exclusion Criteria:
- The subject has an active urogenital infection or active skin infection in region of
surgery.
- The subject has confirmed Pelvic Organ Prolapse (POP) of Stage 2 or higher as
determined by POP-Q prolapse grading.
- The subject is having a concomitant pelvic floor procedure.
- The subject has incontinence due to neurogenic causes (e.g. multiple sclerosis, spinal
cord/brain injury, cerebrovascular accident, detrusor-external sphincter dyssynergia,
Parkinson's disease, or similar conditions).
- The subject had a prior surgical stress urinary incontinence (SUI) treatment.
- The subject has undergone radiation or brachy therapy to treat pelvic cancer.
- The subject has urge predominant incontinence by MESA assessment.
- The subject has an atonic bladder or post void residual (PVR) above 100 cc on ≥ 2
occasions.
- The subject is pregnant and/or is planning to get pregnant in the future.
- The subject has a contraindication to the surgical procedure or the product
Instructions for Use (IFU).
- The subject is enrolled in a concurrent clinical trial of any treatment (drug or
device) that could affect continence function, without the sponsors approval.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
Female
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kathryn Batham
650-724-7846
I'm interested
Altis® 522 Trial - Treatment of Female Stress Urinary Incontinence
The aim of this postmarket study is to compare the safety and effectiveness of the Altis Single Incision Sling (SIS) to an FDA cleared transobturator and/or retropubic sling through 36 months.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Transobturator or Retropubic Sling
- device: Altis Single Incision Sling
Eligibility
Inclusion Criteria:
- The subject is female and at least 18 years of age.
- The subject is able and willing to complete all procedures and follow-up visits
indicated in this protocol.
- The subject has confirmed stress urinary incontinence (SUI) through cough stress test
or urodynamics.
- The subject has failed two non-invasive incontinence therapies (such as Kegel
exercise, behavior modification, pad use, biofeedback, etc.) for > 6 months.
Exclusion Criteria:
- The subject has an active urogenital infection or active skin infection in region of
surgery.
- The subject has confirmed Pelvic Organ Prolapse (POP) of Stage 2 or higher as
determined by POP-Q prolapse grading.
- The subject is having a concomitant pelvic floor procedure.
- The subject has incontinence due to neurogenic causes (e.g. multiple sclerosis, spinal
cord/brain injury, cerebrovascular accident, detrusor-external sphincter dyssynergia,
Parkinson's disease, or similar conditions).
- The subject had a prior surgical stress urinary incontinence (SUI) treatment.
- The subject has undergone radiation or brachy therapy to treat pelvic cancer.
- The subject has urge predominant incontinence by MESA assessment.
- The subject has an atonic bladder or post void residual (PVR) above 100 cc on ≥ 2
occasions.
- The subject is pregnant and/or is planning to get pregnant in the future.
- The subject has a contraindication to the surgical procedure or the product
Instructions for Use (IFU).
- The subject is enrolled in a concurrent clinical trial of any treatment (drug or
device) that could affect continence function, without the sponsors approval.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
Female
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kathryn Batham
650-724-7846
I'm interested